Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBIT: 2009-2024

Historic EBIT for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$13.7 million.

  • OptimizeRx's EBIT rose 12394.3% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 12393.16%. This contributed to the annual value of -$13.7 million for FY2024, which is 4808.73% up from last year.
  • OptimizeRx's EBIT amounted to -$13.7 million in FY2024, which was up 4808.73% from -$26.4 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's EBIT ranged from a high of $361100.0 in FY2021 and a low of -$26.4 million during FY2023
  • In the last 5 years, OptimizeRx's EBIT had a median value of -$12.3 million in 2022 and averaged -$10.8 million.
  • Per our database at Business Quant, OptimizeRx's EBIT surged by 11691.08% in 2021 and then crashed by 350369.37% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's EBIT stood at -$2.1 million in 2020, then soared by 116.91% to $361100.0 in 2021, then crashed by 3503.69% to -$12.3 million in 2022, then plummeted by 114.81% to -$26.4 million in 2023, then skyrocketed by 48.09% to -$13.7 million in 2024.
  • Its EBIT stands at -$13.7 million for FY2024, versus -$26.4 million for FY2023 and -$12.3 million for FY2022.